Press Room

Pharmaceutical Continuous Manufacturing (PCM) Business Summit

Start
Wednesday, September 27, 2023
End
Wednesday, September 27, 2023
Location: New Jersey, USA

HOVIONE PRESENTATION AT Pharmaceutical Continuous Manufacturing (PCM) Business Summit.

In New Jersey, Sarang Oka – Production Senior Manager, Drug Product Continuous Manufacturing, is hosting a presentation entitled “A short journey in Commercial Manufacturing with PCM” from 3:30 – 4:00 pm.

In this presentation, Sarang will provide a brief glimpse related to the implementation of pharmaceutical continuous manufacturing (tableting) at ɫAV, NJ. He will also discuss some learnings from implementation of continuous tableting in a commercial environment. Case studies will focus on the use of big data sets to assess process health, and how these data sets lend themselves to implement simple analysis tools as SPC.

schedule a meeting

Get to know more onContinuous Tableting

More on the

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024